EBITDA for AstraZeneca (AZN)
According to AstraZeneca's latest reported financial statements, the company's current EBITDA (TTM) is $19.83B USD. EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a common proxy for operating cash generation that strips out non-cash charges (depreciation and amortization) and capital structure effects (interest, taxes). Useful for comparing companies with different leverage and asset bases — see operating income and net income for fully GAAP figures.
Headline TTM above sums the four reported quarters through (reported ). Chart and table below cover the full reported history back to .
AZN
Currently viewingEBITDASwitch metric
TTM (last 4 quarters)
$19.83B
YoY change
+28.4%
5Y CAGR
+19.7%
Peak year (2025)
$19.83B
Cumulative EBITDA
$260.31B
EBITDA history chart for AstraZeneca (AZN) from 1990 to 2025
EBITDA history table for AstraZeneca (AZN) from 1990 to 2025
| Fiscal year | Period ended | Reported | EBITDA | YoY |
|---|---|---|---|---|
| 2025 | $19.83B | +28.4% | ||
| 2024 | $15.44B | +15.0% | ||
| 2023 | $13.42B | +47.7% | ||
| 2022 | $9.09B | +77.7% | ||
| 2021 | $5.11B | -36.8% | ||
| 2020 | $8.08B | +20.4% | ||
| 2019 | $6.71B | -5.6% | ||
| 2018 | $7.11B | +7.4% | ||
| 2017 | $6.62B | -9.0% | ||
| 2016 | $7.28B | +4.5% | ||
| 2015 | $6.96B | +26.8% | ||
| 2014 | $5.49B | -34.2% | ||
| 2013 | $8.34B | -21.9% | ||
| 2012 | $10.68B | -30.6% | ||
| 2011 | $15.39B | +4.4% | ||
| 2010 | $14.74B | +5.7% | ||
| 2009 | $13.95B | +10.5% | ||
| 2008 | $12.62B | +26.8% | ||
| 2007 | $9.95B | +4.1% | ||
| 2006 | $9.56B | +22.1% | ||
| 2005 | $7.83B | +34.6% | ||
| 2004 | $5.82B | +9.7% | ||
| 2003 | $5.30B | +6.7% | ||
| 2002 | $4.97B | -1.0% | ||
| 2001 | $5.02B | +2.1% | ||
| 2000 | $4.91B | +9.2% | ||
| 1999 | $4.50B | +38.5% | ||
| 1998 | $3.25B | +44.7% | ||
| 1997 | $2.24B | +4.4% | ||
| 1996 | $2.15B | +59.1% | ||
| 1995 | $1.35B | -8.5% | ||
| 1994 | $1.48B | +6.0% | ||
| 1993 | $1.39B | +102.8% | ||
| 1992 | $687.06M | -59.1% | ||
| 1991 | $1.68B | +22.2% | ||
| 1990 | $1.37B | — |
EBITDA values are taken from AstraZeneca's reported income statements (10-Q quarterly and 10-K annual filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the date the filing was reported; YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
Analysis
The 2025 reading of AstraZeneca (AZN) EBITDA is $19.83B – grew 28.4% year-over-year.
Through 2020–2025 (5 years), AstraZeneca EBITDA delivered a +19.7% annualised rate; sustaining 4 straight years of year-over-year growth.
Across the available history, EBITDA reached its high of $19.83B in 2025 and its low of $687.06M in 1992.
Within Healthcare, AstraZeneca (AZN) ranks 6th among 8 peers we track. The peer median for EBITDA is $24.21B.
AstraZeneca EBITDA by Year
AstraZeneca EBITDA 2025: $19.83B
AstraZeneca EBITDA in 2025 was $19.83B, grew 28.4% from 2024. This figure represents the highest annual value in the available history.
AstraZeneca EBITDA 2024: $15.44B
AstraZeneca EBITDA in 2024 was $15.44B, grew 15.0% from 2023.
AstraZeneca EBITDA 2023: $13.42B
AstraZeneca EBITDA in 2023 was $13.42B, surged 47.7% from 2022.
AstraZeneca EBITDA 2022: $9.09B
AstraZeneca EBITDA in 2022 was $9.09B, surged 77.7% from 2021.
AstraZeneca EBITDA 2021: $5.11B
AstraZeneca EBITDA in 2021 was $5.11B.
See more financial history for AstraZeneca (AZN).
Sector peers — EBITDA
Companies in the same sector as AstraZeneca, ranked by their latest EBITDA.
| Company | EBITDA | Sector |
|---|---|---|
| Novo Nordisk A/S (NVO) | $156.73B | Healthcare |
| Johnson & Johnson (JNJ) | $41.05B | Healthcare |
| Eli Lilly and Company (LLY) | $27.94B | Healthcare |
| Merck & Co., Inc. (MRK) | $25.36B | Healthcare |
| UnitedHealth Group Incorporated (UNH) | $23.06B | Healthcare |
| AbbVie Inc. (ABBV) | $17.63B | Healthcare |
| Amgen Inc. (AMGN) | $15.84B | Healthcare |
| Thermo Fisher Scientific Inc. (TMO) | $11.47B | Healthcare |
Frequently asked questions
What is AstraZeneca's EBITDA?
- Latest reported EBITDA for AstraZeneca (AZN) is $19.83B (period ending December 31, 2025).
How has AstraZeneca EBITDA changed year-over-year?
- AstraZeneca (AZN) EBITDA changed +28.4% year-over-year on the latest annual filing.
What is the long-term growth rate of AstraZeneca EBITDA?
- AstraZeneca (AZN) EBITDA compound annual growth rate is +19.7% over the most recent 5 years available.
When did AstraZeneca EBITDA hit its highest annual value?
- AstraZeneca EBITDA reached its highest annual value of $19.83B in 2025.
What was AstraZeneca EBITDA in 2024?
- AstraZeneca (AZN) EBITDA in 2024 was $15.44B.
What was AstraZeneca EBITDA in 2025?
- AstraZeneca (AZN) EBITDA in 2025 was $19.83B.
Metrics overview
Pick a metric for charts, filings, and peers — each row shows the latest TTM or annual value with year-over-year change.
Explore more
AZN Overview
Company profile, financial tools, and key metrics
AZN Revenue Counter
Earns $1,863 every second. See per minute, hour, and day.
AZN Earnings Counter
Earns $324.23 per second net profit. See per minute, hour, and day.
AZN Economic Scale
Exceeds Bolivia's GDP. Compare with world economies.
AZN What If Invested
What if you had invested $1,000? See historical returns from any date.
AZN How It Makes Money
Discover visual breakdown of $58.74B in revenue — where it comes from and where it goes.
AZN Stock Seasonality
Best and worst months to invest. Historical monthly returns heatmap.
AZN Price Target Scenarios
Model bear, base, and bull cases with EPS growth and exit P/E — pre-filled from analysts and history.
AZN Daily Price Character
Steady · 49.4% historical win rate (green days). Streaks & record days.
AZN Buybacks
0.16% TTM buyback yield. Shareholder yield & SBC comparison.
AZN Stock Split History
3 splits on record. Dates, ratios, and cumulative multiple.
AZN Dividend Profile
Yield: 1.73%. Safety: 6/8. See full history.
AZN Dividend Calculator
How much dividend income would $1,000 have earned? Calculate from any date.
AZN Dividend Forecast
Project future income with DRIP, growth assumptions, and optional monthly contributions.